Hofseth Biocare

Hofseth Biocare, a pharmaceutical preparation manufacturing company headquartered in Norway, has reported its carbon emissions for several years. In 2024, the company's total emissions were approximately 14,930,000 kg CO2e. This total includes Scope 1 emissions of about 1,616,000 kg CO2e and Scope 2 emissions of approximately 15,000 kg CO2e. Scope 3 emissions, specifically purchased goods and services, accounted for about 11,368,000 kg CO2e, with upstream transportation and distribution contributing around 445,000 kg CO2e and downstream transportation and distribution at approximately 1,453,000 kg CO2e.

For 2023, Hofseth Biocare reported Scope 1 emissions of approximately 1,850,000 kg CO2e and Scope 2 emissions of about 15,000 kg CO2e, with Scope 3 data not fully disclosed. In 2022, Scope 1 emissions were reported as roughly 2,104,000 kg CO2e and Scope 2 at approximately 15,000 kg CO2e. The company's disclosures for 2021 show Scope 1 emissions of about 1,810,000 kg CO2e and Scope 2 emissions of approximately 45,000 kg CO2e. In 2020, Scope 1 emissions were recorded at about 1,619,000 kg CO2e, with Scope 2 emissions at approximately 90,400 kg CO2e.

Hofseth Biocare's disclosures indicate a commitment to reporting on its environmental impact, with increasing transparency in its emissions reporting over the years, particularly by including Scope 3 categories in its most recent reports. While specific reduction targets and SBTi commitments are not detailed in the provided data, the company's ongoing reporting demonstrates a focus on monitoring and understanding its carbon footprint within the pharmaceutical manufacturing sector.